Tag Archive for ‘FDA’ 
Biopharm Stock on the Move; BioCryst rebounds on Rumors of increased Influenza Incidence
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares recovered 16% in the second half of March, on speculations that the increased flu incidence this spring as well as bigger government stockpiling could boost the sales of the company’s influenza drug Peramavir. In addition, the earthquake and subsequent tsunami in Japan created the circumstances for increased transmission of influenza virus through the high - Continue Reading »
Moment of truth: Human Genome Sciences: Blockbuster Drug Candidate awaits FDA Verdict
Shares of Human Genome Sciences Inc. (Nasdaq: HGSI) have swung up and down around $25.50 since November when the U.S. Food and Drug Administration (FDA) advisory panel voted 13-2 to recommend the approval of the company’s systemic lupus erythematosus (lupus) drug, Benlysta. The FDA required more information on Benlysta and scheduled the final ruling by March 10, 2011. With a - Continue Reading »
Stock on Top; Jazz Pharmaceuticals surges on Record Results and Superior Outlook
The shares of Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) hit a new record in the after-hours session on March 7, after the company reported strong results for Q4 2010 and posted a guidance for 2011, which topped the market estimates. JAZZ closed the regular session at $27.30 and surged 5.5% to $28.79 in the extended action. - Continue Reading »
Top Biopharm Alert – Allos Therapeutics Rebounds on Potential Expansion of Folotyn Reach
Allos Therapeutics Inc. (NASDAQ: ALTH) soared 6.45% to $3.30 during the afterhours session yesterday, gaining nearly 5% in today’s early trading as the company’s results for Q4 2010 run above the analyst expectations. In addition, Allos announced that the Food and Drug Administration (FDA) agreed on phase III clinical trial of its lead drug Folotyn in patients with previously undiagnosed - Continue Reading »
